Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12702532rdf:typepubmed:Citationlld:pubmed
pubmed-article:12702532lifeskim:mentionsumls-concept:C1414121lld:lifeskim
pubmed-article:12702532lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:12702532lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:12702532lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:12702532lifeskim:mentionsumls-concept:C1709518lld:lifeskim
pubmed-article:12702532lifeskim:mentionsumls-concept:C0556985lld:lifeskim
pubmed-article:12702532lifeskim:mentionsumls-concept:C1521801lld:lifeskim
pubmed-article:12702532lifeskim:mentionsumls-concept:C0796640lld:lifeskim
pubmed-article:12702532pubmed:issue5lld:pubmed
pubmed-article:12702532pubmed:dateCreated2003-4-18lld:pubmed
pubmed-article:12702532pubmed:abstractTextHypermethylation and inactivation of tumor suppressor genes by the enzyme DNA methyltransferase may lead to neoplastic transformation. MG98, a phosphorothioate antisense oligodeoxynucleotide that is a specific inhibitor of mRNA for human DNA methyltransferase 1 (DNMT1), was evaluated in a phase I study.lld:pubmed
pubmed-article:12702532pubmed:languageenglld:pubmed
pubmed-article:12702532pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12702532pubmed:citationSubsetIMlld:pubmed
pubmed-article:12702532pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12702532pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12702532pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12702532pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12702532pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12702532pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12702532pubmed:statusMEDLINElld:pubmed
pubmed-article:12702532pubmed:monthMaylld:pubmed
pubmed-article:12702532pubmed:issn0923-7534lld:pubmed
pubmed-article:12702532pubmed:authorpubmed-author:StewartD JDJlld:pubmed
pubmed-article:12702532pubmed:authorpubmed-author:BonfilsCClld:pubmed
pubmed-article:12702532pubmed:authorpubmed-author:DonehowerR...lld:pubmed
pubmed-article:12702532pubmed:authorpubmed-author:MacLeodA RARlld:pubmed
pubmed-article:12702532pubmed:authorpubmed-author:BestermanJ...lld:pubmed
pubmed-article:12702532pubmed:authorpubmed-author:ShahA KAKlld:pubmed
pubmed-article:12702532pubmed:authorpubmed-author:EisenhauerE...lld:pubmed
pubmed-article:12702532pubmed:authorpubmed-author:ReidG KGKlld:pubmed
pubmed-article:12702532pubmed:authorpubmed-author:WainmanNNlld:pubmed
pubmed-article:12702532pubmed:issnTypePrintlld:pubmed
pubmed-article:12702532pubmed:volume14lld:pubmed
pubmed-article:12702532pubmed:ownerNLMlld:pubmed
pubmed-article:12702532pubmed:authorsCompleteYlld:pubmed
pubmed-article:12702532pubmed:pagination766-74lld:pubmed
pubmed-article:12702532pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:meshHeadingpubmed-meshheading:12702532...lld:pubmed
pubmed-article:12702532pubmed:year2003lld:pubmed
pubmed-article:12702532pubmed:articleTitleA phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly.lld:pubmed
pubmed-article:12702532pubmed:affiliationOttawa Regional Cancer Centre, Ottawa, ON, Canada.lld:pubmed
pubmed-article:12702532pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12702532pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12702532pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:12702532pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12702532lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12702532lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12702532lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12702532lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12702532lld:pubmed